Treating tumors caused by overactive Ras in Neurofibromatosis type 1 (NF1)
Developmental and Hyperactive Ras Tumor (DHART) SPORE
This program develops new targeted treatments for tumors that happen in people with Neurofibromatosis type 1 (NF1), with a focus on children, adolescents, and young adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11181004 on NIH RePORTER |
What this research studies
This SPORE focuses on NF1, a genetic condition that causes tumors by overactive Ras signaling. From a patient perspective, researchers will use lab models, patient tumor samples, and clinical expertise to develop and refine targeted drug approaches. The team will study why some tumors respond to therapy while others become resistant and will push promising leads toward clinical testing. The work brings together basic science and clinical care at Indiana University and partner sites to move treatments toward people who need them.
Who could benefit from this research
Good fit: Ideal candidates are people with NF1 who have tumors driven by Ras signaling, especially children, adolescents, and young adults with plexiform neurofibromas or other NF1-associated malignancies.
Not a fit: People without NF1 or whose tumors are not driven by Ras pathway mutations are unlikely to benefit directly from this program.
Why it matters
Potential benefit: If successful, the program could deliver new targeted therapies that shrink NF1-related tumors and improve symptoms, function, and survival.
How similar studies have performed: Some targeted approaches such as MEK inhibitors have helped certain NF1 tumors, but resistance and other tumor types remain challenges that this program aims to address.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Clapp, David W — Indiana University Indianapolis
- Study coordinator: Clapp, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.